Table 1.
Characteristics of the patients included in the cross-sectional evaluation
| Characteristics | Active LN Mexican Cohort (n=120) | Active LN OSU Cohort (n=129) | iLN (n=70) | Healthy Kidney Donors (n=31) | |
|---|---|---|---|---|---|
| iSLE (n=40) | Active Extrarenal SLE (n=30) | ||||
| Age, yr | 32 (25–39) | 31 (26–40) | 44 (30–57) | 42 (27–50) | 34 (29–41) |
| Female, n (%) | 108 (90) | 106 (82) | 37 (93) | 27 (90) | 23 (74) |
| Race, n (%) | |||||
| White | 1 (1) | 61 (47) | 5 (13) | 16 (53) | 12 (39) |
| Black | 0 (0) | 56 (44) | 1 (2) | 10 (33) | 5 (16) |
| Asian | 0 (0) | 4 (3) | 0 (0) | 0 (0) | 0 (0) |
| Mexican Mestizo | 119 (99) | 0 (0) | 34 (85) | 4 (13) | 10 (32) |
| Other | 0 (0) | 8 (6) | 0 (0) | 0 (0) | 4 (13) |
| Creatinine, mg/dl | 1.1 (0.7–2.0) | 0.9 (0.7–1.6) | 0.7 (0.6–0.8) | 0.8 (0.7–0.9) | 0.8 (0.7–0.9) |
| eGFR, ml/min per 1.73 m2 | 68 (35–110) | 90 (48–123) | 105 (90–119) | 98 (85–116) | 101 (96–109) |
| Proteinuria, 24 h g/g | 3.3 (2.2–5.2) | 2.6 (0.9–4.8) | 0.1 (0.0–0.25) | 0.1 (0.0–0.25) | 0.1 (0.0–0.1) |
| Positive dsDNA antibodies | 101 (84) | 89 (69) | 23 (58) | 26 (87) | — |
| C3, mg/dl | 68 (44–88) | 62 (43–86) | 104 (88–122) | 94 (65–109) | — |
| C4, mg/dl | 8 (8–13) | 11 (8–18) | 21 (10–27) | 15 (11–35) | — |
| SLEDAI-2K, points | 16 (14–22) | 17 (9–24) | 0 (0–4) | 17 (10–24) | — |
All values are expressed as median (IQR) or number (relative frequency). eGFR calculated by the CKD-Epidemiology Collaboration formula.